Takeda's Psoriasis Drug Hits Phase 3 Goals, Eyes FDA Approval

Key Facts

In a move that strengthens its position within the competitive immunology sector, Takeda Pharmaceutical announced positive Phase 3 clinical trial data for zasocitinib, its oral psoriasis treatment candidate. The trial results demonstrated significant skin clearance in patients, validating the drug's efficacy as a potential alternative to existing therapies. Following these successful outcomes, the company is preparing to submit a regulatory filing to the U.S. Food and Drug Administration (FDA) shortly.

This breakthrough arrives as the global psoriasis market experiences a shift toward oral medications, with Takeda competing against industry peers like Amgen and Bristol Myers Squibb. According to industry reports, oral treatments are increasingly favored by patients over injectable biologics, and competitors like Sotyktu have already set a high bar for commercial performance. These trial results are particularly vital for Takeda as it seeks to bolster its pipeline amid patent expirations for older blockbuster assets.

Regarding market performance, TAK shares closed at $16.73 (close July 16, 2026), having traded between a day low of $16.49 and a high of $16.76. Investors are now closely monitoring the specific timeline for the FDA filing as the next primary catalyst for the stock. With no major sector-specific events listed in the immediate upcoming calendar, the focus remains on the clinical data's long-term commercial implications.